• News
  • BioTech

Mallinckrodt to acquire Cadence Pharmaceuticals for $1.21B

The health care products company Mallinckrodt is buying San Diego-based Cadence Pharmaceuticals (Nasdaq: CADX) for about $1.21 billion in a bid to strengthen its specialty drugs unit.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments

Cadence Pharmaceuticals Inc.

Company Website

12481 High Bluff Dr. Ste., 200
San Diego, CA 92130

Cadence Pharmaceuticals Inc. Executive(s):

Theodore Schroeder

  • Chief Executive Officer, President

Similar Companies

Subscribe Today!